The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
Early data whet appetites ahead of the big event for one of the few remaining antiviral hopes in Covid-19.
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times.